Skip to main content
SpringerLink
Log in

Cardiovascular Safety Profiles of Aromatase Inhibitors

A Comparative Review

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Third-generation aromatase inhibitors (AIs) are now being used for the adjuvant treatment of postmenopausal women with breast cancer, and are challenging tamoxifen, the previous ‘gold standard’ of care, in this setting. This review evaluates the potential clinical impact of anastrozole, letrozole and exemestane on the cardiovascular (CV) system of postmenopausal women with breast cancer. Some data for CV safety are available for AIs from the advanced disease setting; however, most derive from patients being treated for early disease. CV data on anastrozole for the treatment of early breast cancer were taken from the ATAC trial, in which anastrozole was compared with tamoxifen in the primary adjuvant setting, and the ABCSG trial 8/ARNO 95 combined analysis, in which switching to 3 years of anastrozole after 2 years of tamoxifen was compared with the standard 5 years of tamoxifen adjuvant therapy. Letrozole has been studied in the primary adjuvant setting and the adjuvant sequencing setting in the BIG 1–98 study, as well as in extended adjuvant endocrine therapy after 5 years of tamoxifen in the MA-17 trial. For exemestane, results were reviewed from the IES trial, in which switching to exemestane following 2–3 years of adjuvant tamoxifen was compared with continued tamoxifen treatment.

All these trials clearly confirmed that all three AIs significantly reduce the risk of thromboembolic events compared with tamoxifen. Data on anastrozole versus tamoxifen from the ATAC trial (68 months’ follow-up) showed a similar incidence of myocardial infarctions (MIs), CV deaths and overall deaths for both therapies; however, anastrozole appeared to be associated with a lower incidence of cerebrovascular events compared with tamoxifen. In addition, the ABCSG trial 8/ARNO 95 study reported no difference in terms of MIs for patients switching to anastrozole compared with patients continuing tamoxifen treatment.

Data from BIG 1–98 (26 months’ follow-up) suggested that primary adjuvant treatment with letrozole may be associated with a significantly greater incidence of CV events and a numerical increase of cerebrovascular and cardiac deaths compared with tamoxifen. However, no increase in CV events with letrozole was reported from the MA-17 trial.

In the IES, updated data at 55 months’ median follow up showed no significant difference in the incidence of MIs and cardiac deaths between patients who switched to exemestane compared with those who continued tamoxifen.

In conclusion, a significantly reduced risk of thromboembolic disease was observed for all three AIs compared with tamoxifen. Anastrozole is, at this point, the only AI with a detailed benefit-risk profile from over 5 years’ follow-up in the adjuvant setting. Thus far, no apparent CV-safety concerns have emerged. Preliminary data on letrozole and exemestane suggest that longer follow-up is needed for these two AIs before being able to fully assess their respective long-term CV toxicity profile. The present differences in CV-safety profiles suggest that third-generation AIs should not be considered as equivalents in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX
Table X
Table XI

Similar content being viewed by others

References

  1. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001 Nov; 92(9): 2247–58

    Article  PubMed  CAS  Google Scholar 

  2. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000 Nov; 18(22): 3758–67

    PubMed  CAS  Google Scholar 

  3. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19(10): 2596–606

    PubMed  CAS  Google Scholar 

  4. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23(3): 619–29

    Article  PubMed  CAS  Google Scholar 

  5. Thürlimann B, Kesaviah A, Mouridsen H, et al. BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [meeting abstracts]. J Clin Oncol 2005; 23: 6s

    Google Scholar 

  6. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004 Mar; 350(11): 1081–92

    Article  PubMed  CAS  Google Scholar 

  7. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365 (9451): 60–2

    Google Scholar 

  8. American Heart Association. Heart disease and stroke statistics: 2005 update [online]. Available from URL: http://www americanheart org/presenter jhtml?.identifier = 1928 2005 [Accessed 2005 Oct 31]

  9. Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat Rep 2005; 53(17): 1–89

    PubMed  Google Scholar 

  10. Witteman JCM, Grobbee DE, Kok FJ, et al. Increased risk of atherosclerosis in women after the menopause. BMJ 1989 Mar; 298(6674): 642–4

    Article  PubMed  CAS  Google Scholar 

  11. Pick R, Stamler J, Robard S, et al. The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation 1952; 6: 276–80

    Article  PubMed  CAS  Google Scholar 

  12. Mercuro G, Zoncu S, Cherchi A, et al. Can menopause be considered an independent risk factor for cardiovascular disease? Ital Heart J 2001 Oct; 2(10): 719–27

    PubMed  CAS  Google Scholar 

  13. Proudler AJ, Felton CV, Stevenson JC. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci (Lond) 1992; 83(4): 489–94

    CAS  Google Scholar 

  14. Walton C, Godslan I, Proudler AJ, et al. The effects of the menopause in carbohydrate metabolism in healthy women [abstract]. J Endocrinol 1991; 129Suppl.: A97

    Google Scholar 

  15. Scarabin PY, Plu-Bureau G, Bara L, et al. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70(4): 584–7

    PubMed  CAS  Google Scholar 

  16. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997 Jul; 78(1): 133–6

    PubMed  CAS  Google Scholar 

  17. Schmitt M, Kuhn W, Harbeck N, et al. Thrombophilic state in breast cancer. Semin Thromb Hemost 1999; 25(2): 157–66

    Article  PubMed  CAS  Google Scholar 

  18. Piccioli A, Prandoni P, Ewenstein BM, et al. Cancer and venous thromboembolism. Am Heart J 1996 Oct; 132(4): 850–5

    Article  PubMed  CAS  Google Scholar 

  19. Agnelli G. Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost 1997 Jul; 78(1): 117–20

    PubMed  CAS  Google Scholar 

  20. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000 Nov; 18(22): 3748–57

    PubMed  CAS  Google Scholar 

  21. Gorodeski GI. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol 2002 Jun; 16(3): 329–55

    Article  PubMed  Google Scholar 

  22. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002 Jul; 288(1): 49–57

    Article  PubMed  Google Scholar 

  23. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000 Aug; 343(8): 522–9

    Article  PubMed  CAS  Google Scholar 

  24. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002 Jul; 288(1): 58–66

    Article  PubMed  CAS  Google Scholar 

  25. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998 Aug; 280(7): 605–13

    Article  PubMed  CAS  Google Scholar 

  26. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33

    Google Scholar 

  27. Chen S. Aromatase and breast cancer. Front Biosci 1998 Aug; 3: 922–d933

    Google Scholar 

  28. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001 Sep; 7(9): 2620–35

    PubMed  CAS  Google Scholar 

  29. Fantidis P, Perez De Prada T, Fernandez-Ortiz A, et al. Morning cortisol production in coronary heart disease patients. Eur J Clin Invest 2002 May; 32(5): 304–8

    Article  PubMed  CAS  Google Scholar 

  30. Goss P, Ingle J, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17 trial. J Natl Cancer Inst 2005; 97(17): 1262–71

    Article  PubMed  CAS  Google Scholar 

  31. Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of “Arimidex” (anastrozole; ZD1033): a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996 Jul; 58(4): 439–45

    Article  PubMed  CAS  Google Scholar 

  32. Esparza-Guerra L, Buzdar A. Anastrozole ‘Arimidex’ does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 2001; 20: 53b

    Google Scholar 

  33. Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999; 35(2): 208–13

    Article  PubMed  CAS  Google Scholar 

  34. Johannessen DC, Engan T, di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997 Jul; 3(7): 1101–8

    PubMed  CAS  Google Scholar 

  35. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20(3): 751–7

    Article  PubMed  CAS  Google Scholar 

  36. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998 Sep; 4(9): 2089–93

    PubMed  CAS  Google Scholar 

  37. Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003 Nov; 39(16): 2318–27

    Article  PubMed  CAS  Google Scholar 

  38. Dewar J, Nabholtz J-MA, Bonneterre J, et al. The effect of anastrozole (Arimidex™) on serum lipids: data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 2000; 64Suppl.: S51

    Google Scholar 

  39. Wojtacki J, Lesniewski-Kmak K, Pawlak W, et al. Anastrozole therapy and lipid profile: an update [abstract]. Eur J Cancer Suppl 2004; 2(3): 142

    Article  Google Scholar 

  40. Wojtacki J, Lesniewski-Kmak K. Biochemical markers of the risk for cardiovascular disease in women with early breast cancer treated with anastrozole [abstract]. Eur J Cancer Suppl 2005; 3(2): 105

    Google Scholar 

  41. Banerjee S, Smith IE, Folkerd L, et al. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005; 16: 1632–8

    Article  PubMed  CAS  Google Scholar 

  42. Wojtacki J, Lesniewski-Kmak K, Piotrowska M, et al. Effect of anastrozole on serum levels of apolipoprotein A-I and B in patients with early breast cancer: additional data on lack of atherogenic properties [abstract]. Breast Cancer Res Treat 2004; 88: S238

    Google Scholar 

  43. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37(12): 1510–3

    Article  PubMed  CAS  Google Scholar 

  44. Wasan KM, Goss P, Pritchard P, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA. 17L). Ann Oncol 2005; 16: 707–15

    Article  PubMed  CAS  Google Scholar 

  45. Engan T, Krane J, Johannessen DC, et al. Plasma changes in breast cancer patients during endocrine therapy: lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995; 36(3): 287–97

    Article  PubMed  CAS  Google Scholar 

  46. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’. Ann Oncol 2004 Feb; 15(2): 211–7

    Article  PubMed  CAS  Google Scholar 

  47. Kataja V, Hietanen P, Joensuu H, et al. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - a randomised study [abstract]. Breast Cancer Res Treat 2002; 76Suppl. 1: S156

    Google Scholar 

  48. McCloskey E, Eastell R, Lakner G, et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenipausal women [abstract no. 2052]. San Antonio (TX): San Antonio Breast Cancer Symposium; 2005 Dec

    Google Scholar 

  49. The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002 Jun; 359 (9324): 2131–9

  50. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000 Apr; 18(7): 1399–411

    PubMed  CAS  Google Scholar 

  51. Baum M, Buzdar A, Cusick J, et al. for the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98(9): 1802–10

    Article  PubMed  CAS  Google Scholar 

  52. The Arimidex, Tamoxifen Alone of in Combination (ATAC) Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006 Aug; 7 (8): 633–43

    Google Scholar 

  53. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005 Aug; 366(9484): 455–62

    Article  PubMed  CAS  Google Scholar 

  54. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005; 23(22): 5138–47

    Article  PubMed  CAS  Google Scholar 

  55. Coombes RC, Hall E, Snowdon CF, et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen: updated survival analysis [abstract]. Breast Cancer Res Treat 2004; 88Suppl. 1: S7

    Google Scholar 

  56. Coombes RC, Paridaens R, Jassem J, et al. First mature survival analysis of the Intergroup Exemestane Study: a randomized trial in disease-free postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. J Clin Oncol 2006; 24(18S): 9S (Abstr LBA527)

    Google Scholar 

  57. Nabholtz JM. Comparison of cardiovascular (CV) safety profiles of aromatase inhibitors (AIs). Abstract presented at ECCO 13 - the European Cancer Conference, joint with ESTRO; 2005 Oct 30-Nov 3; Paris, France

Download references

Acknowledgements

The authors would like to thank Dr Sarah Goodger from CMC, who provided partial medical writing and editing support. Dr Goodger’s services were covered by a grant from AstraZeneca. No other funding was received for the preparation of this paper. Professor Nabholtz is a member of the AstraZeneca Speakers Bureau. Dr Gligorov has no conflicts of interest relevant to the contents of this review.

Author information

Authors and Affiliations

  1. Breast Cancer Research Institute, La Prandie, 24290, Valojoulx, Paris, France

    Jean-Marc Nabholtz

  2. Medical Oncology Department, CancerEst APHP Tenon, Paris, France

    Joseph Gligorov

Authors
  1. Jean-Marc Nabholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Gligorov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Marc Nabholtz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nabholtz, JM., Gligorov, J. Cardiovascular Safety Profiles of Aromatase Inhibitors. Drug-Safety 29, 785–801 (2006). https://doi.org/10.2165/00002018-200629090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629090-00003

Keywords

Search

Navigation